

DT07 Rec. CT/PTO 08 FEB 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85258

MIKOSHIBA, Imao, et al.

Appln. No.: 10/519,155

Group Art Unit: NOT YET ASSIGNED

Confirmation No.: NOT YET ASSIGNED

Examiner: NOT YET ASSIGNED

Filed: December 27, 2004

For: DRUG COMPOSITION FOR PREVENTION OR INHIBITION OF ADVANCE OF
DIABETIC COMPLICATION

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/519,155

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


These are the references listed in the International Search Report. Some of the references are originally written in Japanese, so the corresponding US or EP patent application publication, or the Japanese original document with the abstract written in English is enclosed.

- (1) US2003/0040490 A1 (cited as X and Y).
- (2) EP1179342 A1 (cited as Y).
- (3) JP2000-26292 A (cited as Y); the full text is available only in Japanese, so the English abstract is enclosed.
- (4) Japanese Journal of Clinical Medicine, 1997, Special extra issue, Vol. 55, pp. 171-179 (cited as A); the full text and the abstract are available only in Japanese.
- (5) Drugs of the Future, 2000, Vol. 20, No. 10, pp. 1034-1042 (cited as A).

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/519,155

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 8, 2005

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Application Number	10/519,155
Confirmation Number	NOT YET ASSIGNED
Filing Date	December 27, 2004
First Named Inventor	MIKOSHIBA, Imao
Art Unit	NOT YET ASSIGNED
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	Q85258

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2003/0040490	A1	02-27-2003	Sugiyama et al.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	1 179 342	A1	02-13-2002	Kissei Pharmaceutical Co., Ltd	English
		JP	2000-26292		01-25-2000	Kissei Pharmaceutical Co., Ltd.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Japanese Journal of Clinical Medicine, 1997, Special extra issue, Vol. 55, pp. 171-179	No
		Drugs of the Future, 2000, Vol. 20, No. 10, pp. 1034-1042	English

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.